Rebecca Sconza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rebecca Sconza has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Anna Samarina
St Petersburg Centre for AIDS and Infectious Diseases St Petersburg Russian Federation
2 shared publicationsChristian Kahlert
Children's Hospital of Eastern Switzerland, St Gallen, Switzerland
2 shared publicationsClaire Thorne
UCL Great Ormond Street Institute of Child Health, University College London
2 shared publicationsHelen Peters
UCL Great Ormond Street Institute of Child Health University College London London UK
2 shared publicationsLuminita Ene
“Dr Victor Babes” Hospital of Infectious and Tropical Diseases, Bucharest, Romania
2 shared publicationsMarta Illán Ramos
Hospital Universitario Clínico San Carlos Madrid Spain
2 shared publications
Latest Publications
- Open Access
- 8 November 2026
- Published by Wiley in HIV Medicine
Pregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaboration
Objective: We aimed to assess ‘real‐world’ pregnancy and neonatal outcomes following prenatal dolutegravir (DTG) use in a European setting. Methods: We conducted a pooled analysis of individual‐patient data from seven observational studies. Pregnancies with DTG exposure any time from the periconception period (≤6 completed gestational weeks) were included. Congenital anomalies were assessed using criteria defined by the World Health Organization International Classification of Diseases: Tenth Revision (ICD‐10) and the European Network of population‐based registries for the epidemiological surveillance of congenital anomalies (EUROCAT). Results: Of 827 pregnancies, there were 764 live births, 37 miscarriages, 21 terminations and five stillbirths. No congenital anomalies were identified in the five stillborn infants. One termination was due to an identified congenital anomaly. Excluding four infants with chromosomal abnormalities, 34 live‐born infants had 37 anomalies. There were no central nervous system abnormalities. Live birth prevalence of congenital anomalies was 4.4% (95% CI 3.0, 6.1) according to ICD‐10; for infants with earliest DTG exposure in the periconception period, later in the first trimester and in the second/third trimester, prevalence was 4.7% (22/470), 2.6% (1/38) and 4.1% (11/265), respectively. Prevalence according to EUROCAT classification was 3.5% (95% CI 2.3, 5.0) overall. In live‐born singletons with earliest exposure at periconception/first trimester and second/third trimesters, 13.6% (66/485) and 13.7% (32/255) were preterm and 9.7% (46/474) and 6.5% (16/246) were small for gestational age, respectively. Conclusions: Our data on prenatal DTG use do not demonstrate increased risk of congenital anomalies compared to expected rates. Ongoing monitoring is needed to exclude association with rare anomalies.
- 8 November 2026
- Published by Wiley in HIV Medicine
Open AccessPregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaboration
Objective: We aimed to assess ‘real‐world’ pregnancy and neonatal outcomes following prenatal dolutegravir (DTG) use in a European setting. Methods: We conducted a pooled analysis of individual‐patient data from seven observational studies. Pregnancies with DTG exposure any time from the periconception period (≤6 completed gestational weeks) were included. Congenital anomalies were assessed using criteria defined by the World Health Organization International Classification of Diseases: Tenth Revision (ICD‐10) and the European Network of population‐based registries for the epidemiological surveillance of congenital anomalies (EUROCAT). Results: Of 827 pregnancies, there were 764 live births, 37 miscarriages, 21 terminations and five stillbirths. No congenital anomalies were identified in the five stillborn infants. One termination was due to an identified congenital anomaly. Excluding four infants with chromosomal abnormalities, 34 live‐born infants had 37 anomalies. There were no central nervous system abnormalities. Live birth prevalence of congenital anomalies was 4.4% (95% CI 3.0, 6.1) according to ICD‐10; for infants with earliest DTG exposure in the periconception period, later in the first trimester and in the second/third trimester, prevalence was 4.7% (22/470), 2.6% (1/38) and 4.1% (11/265), respectively. Prevalence according to EUROCAT classification was 3.5% (95% CI 2.3, 5.0) overall. In live‐born singletons with earliest exposure at periconception/first trimester and second/third trimesters, 13.6% (66/485) and 13.7% (32/255) were preterm and 9.7% (46/474) and 6.5% (16/246) were small for gestational age, respectively. Conclusions: Our data on prenatal DTG use do not demonstrate increased risk of congenital anomalies compared to expected rates. Ongoing monitoring is needed to exclude association with rare anomalies.
- Open Access
- 11 February 2026
- Published by Wolters Kluwer Health in AIDS
- Vol. 40 (6) , 831-839
Dosing of ritonavir-boosted darunavir for treatment of HIV in pregnancy
Objective: To assess the effectiveness of once- and twice-daily ritonavir-boosted darunavir (DRV/r)-containing regimens for treating HIV in pregnancy to inform the 2025 World Health Organization antiretroviral treatment guidelines update. Design: Analysis of pooled data from two observational study networks with sites in Romania, Switzerland, and the United Kingdom. Methods: Pregnancies resulting in a live birth or stillbirth in women receiving 800/100 mg DRV/r once-daily or 600/100 mg twice-daily during pregnancy were included. The primary outcome was viral suppression (<50 copies/ml) near delivery (from 28 days prior to 7 days after delivery). Results: Among 162 women on once-daily DRV/r, 95% were virally suppressed near delivery, with no difference between those on DRV/r from conception (95%, 113/119) and those who started on or switched to DRV/r during pregnancy (95%, 41/43). Among 27 women on twice-daily DRV/r, 78% were virally suppressed near delivery. Most women remained on the same DRV/r regimen until delivery, and there were no vertical transmissions. Darunavir drug concentrations for the limited number of pregnancies with data available fell within the expected ranges. Conclusions: This analysis provides some reassurance that once-daily DRV/r can be used successfully in pregnancy. However, given the possibility of reduced drug levels in pregnancy with once-daily dosing, viral load monitoring during pregnancy remains essential. Surveillance of pregnancies in women receiving once-daily DRV/r is needed to further support the use of this dosing during pregnancy.
- 11 February 2026
- Published by Wolters Kluwer Health in AIDS
- Vol. 40 (6) , 831-839
Open AccessDosing of ritonavir-boosted darunavir for treatment of HIV in pregnancy
Objective: To assess the effectiveness of once- and twice-daily ritonavir-boosted darunavir (DRV/r)-containing regimens for treating HIV in pregnancy to inform the 2025 World Health Organization antiretroviral treatment guidelines update. Design: Analysis of pooled data from two observational study networks with sites in Romania, Switzerland, and the United Kingdom. Methods: Pregnancies resulting in a live birth or stillbirth in women receiving 800/100 mg DRV/r once-daily or 600/100 mg twice-daily during pregnancy were included. The primary outcome was viral suppression (<50 copies/ml) near delivery (from 28 days prior to 7 days after delivery). Results: Among 162 women on once-daily DRV/r, 95% were virally suppressed near delivery, with no difference between those on DRV/r from conception (95%, 113/119) and those who started on or switched to DRV/r during pregnancy (95%, 41/43). Among 27 women on twice-daily DRV/r, 78% were virally suppressed near delivery. Most women remained on the same DRV/r regimen until delivery, and there were no vertical transmissions. Darunavir drug concentrations for the limited number of pregnancies with data available fell within the expected ranges. Conclusions: This analysis provides some reassurance that once-daily DRV/r can be used successfully in pregnancy. However, given the possibility of reduced drug levels in pregnancy with once-daily dosing, viral load monitoring during pregnancy remains essential. Surveillance of pregnancies in women receiving once-daily DRV/r is needed to further support the use of this dosing during pregnancy.
- Open Access
- 1 June 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (2) , 158-165
Outcomes After Prenatal Exposure to Raltegravir-Containing Antiretroviral Therapy: A Multicohort European Study
Background: Raltegravir is an HIV integrase strand transfer inhibitor recommended for use in pregnancy. The aim of this study was to assess risk of birth defects and other suboptimal outcomes after prenatal exposure to raltegravir. Methods: We used pooled, prospectively collected individual patient data from studies in the European Pregnancy and Paediatric Infections Cohort Collaboration. Pregnancies with any prenatal exposure to raltegravir with outcomes in 2008–2020 were included. Birth defects were classified according to World Health Organization's International Classification of Diseases and EUROCAT criteria. Earliest prenatal exposure timing was classified as periconception [exposure at ≤6 completed gestational weeks (GWs)], later first trimester (T1) (exposure in T1 at >6 completed GWs), and second/third trimester (exposure at >12 completed GWs). Results: A total of 1499 pregnancies across 9 cohorts were included. Where timing was available (n = 1449), earliest raltegravir exposure was in the periconception period for 505 (34.8%), later T1 in 65 (4.5%), and T2/T3 in 879 (60.7%). The overall prevalence of birth defects among live-born infants with prenatal raltegravir exposure was 3.9% (95% confidence interval: 2.9, 5.0) (1443/1466) (International Classification of Diseases), with no increased risk observed for those exposed in the periconception period (P = 0.290). Among singleton live-born infants, 11.9% (160/1346) were born preterm, 11.3% (148/1307) low birthweight, and 8.6% (111/1291) small for gestational age, with no difference in outcomes observed by timing of raltegravir exposure. Conclusions: These findings add to the evidence base around safety of raltegravir use in pregnancy, although ongoing safety monitoring is needed to rule out risk of rare outcomes.
- 1 June 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (2) , 158-165
Open AccessOutcomes After Prenatal Exposure to Raltegravir-Containing Antiretroviral Therapy: A Multicohort European Study
Background: Raltegravir is an HIV integrase strand transfer inhibitor recommended for use in pregnancy. The aim of this study was to assess risk of birth defects and other suboptimal outcomes after prenatal exposure to raltegravir. Methods: We used pooled, prospectively collected individual patient data from studies in the European Pregnancy and Paediatric Infections Cohort Collaboration. Pregnancies with any prenatal exposure to raltegravir with outcomes in 2008–2020 were included. Birth defects were classified according to World Health Organization's International Classification of Diseases and EUROCAT criteria. Earliest prenatal exposure timing was classified as periconception [exposure at ≤6 completed gestational weeks (GWs)], later first trimester (T1) (exposure in T1 at >6 completed GWs), and second/third trimester (exposure at >12 completed GWs). Results: A total of 1499 pregnancies across 9 cohorts were included. Where timing was available (n = 1449), earliest raltegravir exposure was in the periconception period for 505 (34.8%), later T1 in 65 (4.5%), and T2/T3 in 879 (60.7%). The overall prevalence of birth defects among live-born infants with prenatal raltegravir exposure was 3.9% (95% confidence interval: 2.9, 5.0) (1443/1466) (International Classification of Diseases), with no increased risk observed for those exposed in the periconception period (P = 0.290). Among singleton live-born infants, 11.9% (160/1346) were born preterm, 11.3% (148/1307) low birthweight, and 8.6% (111/1291) small for gestational age, with no difference in outcomes observed by timing of raltegravir exposure. Conclusions: These findings add to the evidence base around safety of raltegravir use in pregnancy, although ongoing safety monitoring is needed to rule out risk of rare outcomes.